190 related articles for article (PubMed ID: 23610071)
1. Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer.
Sonego M; Schiappacassi M; Lovisa S; Dall'Acqua A; Bagnoli M; Lovat F; Libra M; D'Andrea S; Canzonieri V; Militello L; Napoli M; Giorda G; Pivetta B; Mezzanzanica D; Barbareschi M; Valeri B; Canevari S; Colombatti A; Belletti B; Del Sal G; Baldassarre G
EMBO Mol Med; 2013 May; 5(5):707-22. PubMed ID: 23610071
[TBL] [Abstract][Full Text] [Related]
2. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis.
Singer S; Ehemann V; Brauckhoff A; Keith M; Vreden S; Schirmacher P; Breuhahn K
Hepatology; 2007 Sep; 46(3):759-68. PubMed ID: 17663418
[TBL] [Abstract][Full Text] [Related]
3. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53.
Alli E; Yang JM; Hait WN
Oncogene; 2007 Feb; 26(7):1003-12. PubMed ID: 16909102
[TBL] [Abstract][Full Text] [Related]
4. Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma.
Ma HL; Jin SF; Ju WT; Fu Y; Tu YY; Wang LZ; Jiang-Li ; Zhang ZY; Zhong LP
J Exp Clin Cancer Res; 2017 Aug; 36(1):109. PubMed ID: 28806997
[TBL] [Abstract][Full Text] [Related]
5. The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53.
Carney BK; Caruso Silva V; Cassimeris L
Cytoskeleton (Hoboken); 2012 May; 69(5):278-89. PubMed ID: 22407961
[TBL] [Abstract][Full Text] [Related]
6. Stathmin/oncoprotein 18, a microtubule regulatory protein, is required for survival of both normal and cancer cell lines lacking the tumor suppressor, p53.
Carney BK; Cassimeris L
Cancer Biol Ther; 2010 May; 9(9):699-709. PubMed ID: 20200495
[TBL] [Abstract][Full Text] [Related]
7. Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses.
Muenyi CS; Pinhas AR; Fan TW; Brock GN; Helm CW; States JC
Toxicol Sci; 2012 May; 127(1):139-49. PubMed ID: 22331493
[TBL] [Abstract][Full Text] [Related]
8. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
9. A delay prior to mitotic entry triggers caspase 8-dependent cell death in p53-deficient Hela and HCT-116 cells.
Silva VC; Plooster M; Leung JC; Cassimeris L
Cell Cycle; 2015; 14(7):1070-81. PubMed ID: 25602147
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.
Bagnoli M; Balladore E; Luison E; Alberti P; Raspagliesi F; Marcomini B; Canevari S; Mezzanzanica D
Mol Cancer Ther; 2007 Feb; 6(2):762-72. PubMed ID: 17308072
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of stathmin expression is mediated directly by Egr1 and associated with p53 activity in lung cancer cell line A549.
Fang L; Min L; Lin Y; Ping G; Rui W; Ying Z; Xi W; Ting H; Li L; Ke D; Jihong R; Huizhong Z
Cell Signal; 2010 Jan; 22(1):166-73. PubMed ID: 19786090
[TBL] [Abstract][Full Text] [Related]
12. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
13. Cell cycle inhibition therapy that targets stathmin in in vitro and in vivo models of breast cancer.
Miceli C; Tejada A; Castaneda A; Mistry SJ
Cancer Gene Ther; 2013 May; 20(5):298-307. PubMed ID: 23618950
[TBL] [Abstract][Full Text] [Related]
14. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.
Karst AM; Levanon K; Duraisamy S; Liu JF; Hirsch MS; Hecht JL; Drapkin R
Gynecol Oncol; 2011 Oct; 123(1):5-12. PubMed ID: 21683992
[TBL] [Abstract][Full Text] [Related]
15. Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells.
Fraser M; Chan SL; Chan SS; Fiscus RR; Tsang BK
Oncogene; 2006 Apr; 25(15):2203-12. PubMed ID: 16288207
[TBL] [Abstract][Full Text] [Related]
16. The individualization of cancer therapy: the unexpected role of p53.
Hait WN; Yang JM
Trans Am Clin Climatol Assoc; 2006; 117():85-101; discussion 101. PubMed ID: 18528466
[TBL] [Abstract][Full Text] [Related]
17. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule.
Soares J; Raimundo L; Pereira NA; Monteiro Â; Gomes S; Bessa C; Pereira C; Queiroz G; Bisio A; Fernandes J; Gomes C; Reis F; Gonçalves J; Inga A; Santos MM; Saraiva L
Oncotarget; 2016 Jan; 7(4):4326-43. PubMed ID: 26735173
[TBL] [Abstract][Full Text] [Related]
19. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells.
Masciarelli S; Fontemaggi G; Di Agostino S; Donzelli S; Carcarino E; Strano S; Blandino G
Oncogene; 2014 Mar; 33(12):1601-8. PubMed ID: 23584479
[TBL] [Abstract][Full Text] [Related]
20. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
